New trial data and updated clinical guidance signal a shift toward precision care

Today’s Gastro Health News Highlights

The landscape of Inflammatory Bowel Disease (IBD) treatment is evolving, with a focus on targeted therapies and real-world evidence. Newer drug classes, such as IL-23 inhibitors and JAK inhibitors, have shown potency in tackling difficult-to-treat manifestations of IBD, including perianal Crohn’s. Research is also focusing on refractory IBD, with investigational combination therapies showing promise. Additionally, efforts to provide better guidance on day-to-day patient management, including the use of NSAIDs and dietary bioactive compounds, are underway. These advancements aim to move away from generalised immunosuppression toward precision medicine, with the goal of achieving sustained, steroid-free remission and improved quality of life for patients.

Real-World Use of Upadacitinib Effective in Perianal Crohn’s

Upadacitinib, a Janus kinase (JAK) inhibitor, has demonstrated significant effectiveness in treating perianal Crohn’s disease (PCD) in a real-world setting. The study reported that the drug was effective in inducing both clinical response and remission in patients, with minimal side effects. This finding confirms the benefits seen in controlled clinical trials, suggesting that upadacitinib offers a valuable option for managing a complication historically difficult to treat with traditional biologics. However, careful monitoring is required due to potential risks such as infection or cardiovascular issues in high-risk groups.

(Source: https://www.medscape.com/index/list_1100_0)

Effectiveness and Safety of Mirikizumab in Ulcerative Colitis

Real-world data from Italy has confirmed that the IL-23 inhibitor mirikizumab is effective for treating ulcerative colitis, achieving clinical remission in half of the patients studied. The research involved patients who had already failed previous biologic therapies, with nearly 51% achieving clinical remission and over 43% achieving steroid-free clinical remission at the 12-week mark. This confirms the strong performance of mirikizumab seen in landmark Phase III trials, providing confidence for clinicians.

(Source: https://bmjopengastro.bmj.com/content/13/1/e002232)

New Combination Therapy Shows Promise for Treatment-Resistant IBD

Emerging clinical data suggests that dual-targeted antibody therapy, blocking two different inflammatory pathways, may offer superior results for patients with highly refractory IBD. The therapy, JNJ-4804, targets both interleukin-23 (IL-23) and tumour necrosis factor-alpha (TNF-α), yielding higher clinical remission and endoscopic response rates in both ulcerative colitis and Crohn’s disease compared to monotherapies. While still investigational, the results offer hope for those who have exhausted standard treatment options.

(Source: https://www.medicalnewstoday.com/articles/treatment-resistant-ibd-may-benefit-new-combo-antibody-therapy)

NSAID Use Not Tied to Hospitalization in Ulcerative Colitis

Research indicates that non-steroidal anti-inflammatory drugs (NSAIDs) do not increase the risk of disease-related hospital admission for ulcerative colitis patients. This is a reassuring finding for UC patients who rely on these drugs for pain relief from co-existing conditions. However, Crohn’s patients should exercise greater caution and consult their doctor before using these medications regularly, as the study observed a small increase in hospitalisation risk for this group.

(Source: https://www.webmd.com/ibd-crohns-disease/inflammatory-bowel-disease)

Bioactive Compounds Show Promise in Complementary IBD Management

A recent review highlighted several dietary bioactive compounds, including curcumin and sulforaphane, for their potential to help manage bowel inflammation through anti-inflammatory pathways. The review found that these compounds show mechanistic plausibility, primarily by modulating anti-inflammatory pathways, enhancing the intestinal barrier, and positively influencing the gut microbiome. While individual responses differ greatly, incorporating specific functional foods or supplements can support IBD management alongside conventional medicine.

(Source: https://www.nutraingredients.com/content/topic/inflammatory-bowel-disease)